Table II.
Efficacy results
| Variable | D + P (N = 118) | C + P (N = 118) | Value of p | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Response: | |||||
| PR [%] | 43 | 36.44 | 36 | 30.51 | 0.33 |
| SD [%] | 58 | 49.15 | 59 | 50.00 | 0.43 |
| PD [%] | 7 | 5.93 | 15 | 12.71 | 0.19 |
| Non-evaluable | 10 | 8.47 | 8 | 6.78 | 0.76 |
| Response rates [%] | 36.44 | 30.51 | 0.04 | ||
| 95% CI | 27.76–45.12 | 22.20–38.82 | |||
| Disease control rates [%] | 85.59 | 80.51. | 0.02 | ||
| 95% CI | 79.26–91.93 | 73.36–87.66 | |||
| PFS, median [months] | 5.6 | 4.7 | 0.31 | ||
| 95% CI | 4.9–6.3 | 4.2–5.2 | |||
| 6 months [%] | 43 | 33 | 0.19 | ||
| Survival, median [months] | 14.9. | 12.9 | 0.37 | ||
| 95% CI | 12.4–17.7 | 10.9–15.1 | |||
| 1 year [%] | 58 | 56 | 0.90 | ||
Response rates were based on intention to treat (ITT). D + P – dicycloplatin plus paclitaxel, C + P – carboplatin plus paclitaxel, PR – partial remission, SD – stable disease, PD – progression disease, PFS – progression-free survival, CI – confidence interval